We serve Chemical Name:4-[2-(2-bromo-5-chlorophenoxy)ethyl]morpholine CAS:1255574-55-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![4-[2-(2-bromo-5-chlorophenoxy)ethyl]morpholine](https://a.dearchem.com/CAS2/1255574-55-0.png)
Chemical Name:4-[2-(2-bromo-5-chlorophenoxy)ethyl]morpholine
CAS.NO:1255574-55-0
Synonyms:2-(2-Morpholinoethoxy)-1-bromo-4-chlorobenzene
Molecular Formula:C12H15BrClNO2
Molecular Weight:320.61000
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:21.70000
Exact Mass:318.99700
LogP:2.75140
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-(2-Morpholinoethoxy)-1-bromo-4-chlorobenzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(2-Morpholinoethoxy)-1-bromo-4-chlorobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(2-Morpholinoethoxy)-1-bromo-4-chlorobenzene Use and application,2-(2-Morpholinoethoxy)-1-bromo-4-chlorobenzene technical grade,usp/ep/jp grade.
Related News: APIs are generally manufactured through a variety of processes that include. 4-[2-(2-bromo-5-chlorophenoxy)ethyl]morpholine manufacturer APIs are generally manufactured through a variety of processes that include. 4-[2-(2-bromo-5-chlorophenoxy)ethyl]morpholine supplier Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. 4-[2-(2-bromo-5-chlorophenoxy)ethyl]morpholine vendor Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. 4-[2-(2-bromo-5-chlorophenoxy)ethyl]morpholine factory ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety.
